The latest news, announcements and press releases from BenevolentAI.
BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.
London, UK, 20 September 2023: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, announces that it has signed a strategic collaboration with Merck, a leading science and technology company headquartered in Darmstadt, Germany.
This is the News section of the company profile page for BenevolentAI on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
